96 related articles for article (PubMed ID: 22368156)
1. Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.
Katna R; Shet T; Sengar M; Menon H; Laskar S; Prabhash K; D'Cruz A; Nair R
Head Neck; 2013 Feb; 35(2):165-71. PubMed ID: 22368156
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
3. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
5. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
Hallermann C; Niermann C; Fischer RJ; Schulze HJ
J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
[TBL] [Abstract][Full Text] [Related]
6. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract][Full Text] [Related]
7. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
8. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
Hu CR; Wang JH; Wang R; Sun Q; Chen LB
Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
[TBL] [Abstract][Full Text] [Related]
9. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
[TBL] [Abstract][Full Text] [Related]
10. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
Connor J; Ashton-Key M
Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
[TBL] [Abstract][Full Text] [Related]
11. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
Li D; Xie P; Mi C
Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
13. Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype.
Sato Y; Onishi N; Morito T; Takata K; Mizobuchi K; Nagatsuka H; Ichimura K; Tanaka T; Tamura M; Yoshino T
Cancer Sci; 2009 Jan; 100(1):42-6. PubMed ID: 19018759
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
15. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
[TBL] [Abstract][Full Text] [Related]
16. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
[TBL] [Abstract][Full Text] [Related]
17. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
[TBL] [Abstract][Full Text] [Related]
18. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
[TBL] [Abstract][Full Text] [Related]
19. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
